CEO Profile

Swey-Shen Chen, D.Sc. is a co-founder of AAIIT. He obtained his M.S. and D.Sc in immunology, epidemiology, and molecular biology at Harvard University, taught as Professor at the Institute of Pathology at Case Western Reserve University Medical School (CWRU) and the University of Nebraska at Lincoln (UNL) and the Medical Center at Omaha (UNMC), and has worked as Principal Investigator at the La Jolla Institute (LJI) and visiting PI and Professor at the Scripps Research Institute (TSRI). He invented IgE immunization, oxidative stress for antigen presentation, and has numerous awarded patents, over a hundred publications, and has been supported by NIAID at NIH for basic research as well as R&D for drug discovery.

What We Do

AAIIT brings innovation of anti-asthma drugs to the market.

The IgE antibody system is a powerful gatekeeper for amplifying inflammation for immune defense in the lung, the GI tracts, and the skin. Elevated IgE levels to allergens and environmental pollutants however, cause allergic asthma, rhinitis, peanut and food allergy, anaphylaxis, and atopic allergic dermatitis.

We invent IgE immunization to down-regulate IgE and alleviate the above IgE-mediated allergic inflammatory disorders:

• IgE immunization product concept has led to the passive mAb anti-IgE Xolair to the market, treating severe allergic asthma.

• An active universal pan-IgE B cell allergy vaccine (UAV), preserving the 3D conformation of mast cell receptor-binding IgE, elicits Xolair-like, broadly neutralizing anti-IgE in mucosal organs and systemic circulation, indicating pan IgE-mediated allergy.

• An active universal natural IgE cytotoxic peptide (nECP) vaccine eliciting cytotoxic T lymphocytes (CTL) and homeostatic regulatory T cells (Treg), suppress IgE production by IgE-producing B and plasma cells, indicating pan IgE-mediated allergy.

Integrating the knowledge of cellular immunology, regulatory biology, molecular biology, peptide chemistry, and protein scaffold technology, we are designing an innovative new generation of anti-allergy drugs with high efficacies and large safety margins. The treatment focuses on allergic inflammation, autoimmune diseases and cancers.

AAIIT Pipelines

ANDI-1

AAIIT has analyzed the effect of the IgE protein and gene in biological systems. The drug lead, ANDI-1 is a conformationally constrained peptide in thermostable protein scaffold that causes antagonism and IgE dissociation from human mast cells as a universal allergen antagonist.

ADIA-1

ADIA_1 is an inverse agonist for desensitization of mast cells and tolerize mast cell degranulation.

mRNA-Immuno-suppressive or tolerogenic vaccines

Using nucleic acid DNA and mRNA tolerization, long-term IgE (36 week sustained unresponsiveness) to Ara h2 is developed